A SINGLE ARM, MULTICENTER, PHASE II, OPEN-LABEL TRIAL TO EVALUATE EFFICACY OF ISATUXIMAB IN PATIENTS WITH MONOCLONAL GAMMOPATHY OF RENAL SIGNIFICANCE
Sponsor: |
Sanofi Genzyme |
Enrolling: |
Male and Female Patients |
IRB Number: |
AAAT0761 |
U.S. Govt. ID: |
NCT04614558 |
Contact: |
Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu |
The purpose of this study is to see whether Isatuximab can help improve kidney function of participants with Monoclonal Gammopathy of Renal Significance (MGRS). Isatuximab is approved by the Food and Drug Administration (FDA) for the treatment of adult patients with multiple myeloma, but it is not approved by the FDA to treat Monoclonal Gammopathy of Renal Significance (MGRS). This means that the use of isatuximab in this study is considered investigational.
Investigator
Divaya Bhutani, MD
Are you at least 18 years old? |
Yes |
No |
Do you have kidney failure and protein in urine? |
Yes |
No |
Have you been diagnosed with Monoclonal Gammopathy of Renal Significance (MGRS)? |
Yes |
No |